A new assay for cell-free DNA fragmentation improves prediction of gene expression in liquid biopsies.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Esfahani, M. S. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01222-4 (2022).
Lo, Y. M. D., Han, D. S. C., Jiang, P. & Chiu, R. W. K. Science 372, eaaw3616 (2021).
Lo, Y. M. et al. Lancet 350, 485–487 (1997).
Chen, X. Q. et al. Nat. Med. 2, 1033–1035 (1996).
Lo, Y. M. et al. Lancet 351, 1329–1330 (1998).
Chan, K. C. A. et al. Clin. Chem. 50, 88–92 (2004).
Zheng, Y. W. L. et al. Clin. Chem. 58, 549–558 (2012).
Jiang, P. et al. Cancer Discov. 10, 664–673 (2020).
Jiang, P. et al. Genome Res. 30, 1144–1153 (2020).
Sun, K. et al. Genome Res. 29, 418–427 (2019).
Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell 164, 57–68 (2016).
Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C. & Seiden, M. V. Ann. Oncol. 31, 745–759 (2020).
Ulz, P. et al. Nat. Genet. 48, 1273–1278 (2016).
Y.M.D.L. holds equity in DRA, Take2 and Grail/Illumina. Y.M.D.L. is a scientific cofounder of Grail. P.J. holds equity in DRA and Grail/Illumina. P.J. is a consultant to Take2. P.J. is a Director of KingMed Future. Patent royalties are received from Grail, Illumina, Sequenom, DRA, Take2 Health and Xcelom.
About this article
Cite this article
Jiang, P., Lo, Y.M.D. Enhanced cancer detection from cell-free DNA. Nat Biotechnol 40, 473–474 (2022). https://doi.org/10.1038/s41587-021-01207-9